Johnson & Johnson agrees to release clinical trial data
Written by Alyssa Clark
Following suit with a number of other major U.S. drug manufactures like GlaxoSmithKline and Medtronic, Johnson & Johnson has finally agreed to allowing its clinical trial research data to go public— such a big step for such a private organization. Feeling the pressure to conform and roll over with the other big names within the pharma industry, apparently J & J felt it was time to spread the truth and let researchers evaluate their clinical trial data. No longer will the FDA be the sole party allowed to tap into the behind the scenes work of pharma giants, but the public will have access to the raw data produced by these billion dollar powerhouses.
With Johnson & Johnson hard at work at up-and-coming drugs for both blood thinners and prostate cancer, it seems interesting that the organization would choose now to jump on board with this trend, but no better time than the present, right?
The company is currently undergoing trials on its highly-anticipated blood thinner Xarelto and its prostate cancer pill Zytiga, as well as further research and development being invested in its artificial hips and knees orthopedics division as well. Harlan Krumholz of Yale University has reported on J&Js openness, seeing that he is assigned to oversee the process of releasing the data to researchers, “You want to know about Listerene trials? They’ll have it.”
“We really wanted a broad approach to contributing to advancing medical science through all of our products that touch patients in different ways,” says Joanne Waldstreicher, MD, Chief Medical Officer, Johnson & Johnson. “Responsible sharing of clinical trial data advances science and medicine and is part of Johnson & Johnson’s commitment to the doctors, nurses, patients, mothers, and fathers and all others who use our products,” said Paul Stoffels, MD, J&J’s chief scientific officer, in a prepared statement.
Although there is expected to be a bit of a learning process for those at Johnson & Johnson, as well as for those who are responsible for collecting and sharing the data, the change is highly-anticipated and welcomed. The process will entail: The Yale School of Medicine’s Open Data Access Project to review requests from physicians and J&J products. This will start with products from the drug division, and will expand to include devices and consumer products as well. If and when the YODA approves the request from the physicians, anonymized data will be provided to the requesting party and it will allow researchers to re-analyze or re-conduct studies in accordance with the new data.
Jvion launches AI-powered map to tackle mental health crisis
Clinical AI company Jvion has launched an interactive map of the US that highlights areas that are most vulnerable to poor mental health.
The Behavioral Health Vulnerability Map uses Jvion's AI CORE™ software to analyse public data on social determinants of health (SDOH) and determine the vulnerability of every US Census block group.
Vulnerability refers to the likelihood that residents will experience issues like self-harm, suicide attempts or overdoses. The map also identifies the most influential social determinants in each region, to show the social and environmental conditions that contribute to mental illness.
As an example, the map shows that Harrison County in Mississippi has a 50% higher suicide rate than the rest of the state. It also shows a high percentage of individuals in the armed forces at a time when active duty suicides are at a six-year high, along with a high prevalence of coronary artery disease, arthritis, and COPD, all chronic illnesses that are linked to a higher suicide risk.
The map also shows Harrison County has a high percentage of Vietnamese Americans, who studies suggest have high rates of depression and may be less likely to seek help from mental health professionals.
The map was built using the same data and analytics that Jvion used to create the COVID Community Vulnerability Map, which was launched towards the start of the pandemic.
With this new map, Jvion is aiming to tackle the growing mental health crisis in the US. “At a time when so many Americans are struggling with their mental health, we’re proud to offer a tool that can help direct treatment resources to the communities that need it most,” said Dr John Showalter, MD, Jvion’s chief product officer, who led the development of the map.
“For too long, the healthcare industry has struggled to address social determinants of health, particularly in the context of behavioural health. Our hope is that by surfacing the social and environmental vulnerabilities of America’s communities, we can better coordinate our response to the underlying conditions that impact the health and wellbeing of people everywhere.”